- Home
- PTHL vs MYNZ Comparison
PTHL vs MYNZ Comparison
Compare PTHL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- MYNZ
- Stock Information
- Founded
- PTHL 1998
- MYNZ 2021
- Country
- PTHL China
- MYNZ Germany
- Employees
- PTHL N/A
- MYNZ N/A
- Industry
- PTHL
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- MYNZ Health Care
- Exchange
- PTHL Nasdaq
- MYNZ Nasdaq
- Market Cap
- PTHL 8.8M
- MYNZ 7.9M
- IPO Year
- PTHL 2024
- MYNZ 2021
- Fundamental
- Price
- PTHL $0.60
- MYNZ $1.06
- Analyst Decision
- PTHL
- MYNZ Strong Buy
- Analyst Count
- PTHL 0
- MYNZ 1
- Target Price
- PTHL N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- PTHL 119.0K
- MYNZ 911.8K
- Earning Date
- PTHL 01-01-0001
- MYNZ 12-29-2025
- Dividend Yield
- PTHL N/A
- MYNZ N/A
- EPS Growth
- PTHL N/A
- MYNZ N/A
- EPS
- PTHL N/A
- MYNZ N/A
- Revenue
- PTHL $448,196.00
- MYNZ $659,935.00
- Revenue This Year
- PTHL N/A
- MYNZ N/A
- Revenue Next Year
- PTHL N/A
- MYNZ $5.03
- P/E Ratio
- PTHL N/A
- MYNZ N/A
- Revenue Growth
- PTHL N/A
- MYNZ N/A
- 52 Week Low
- PTHL $0.47
- MYNZ $0.92
- 52 Week High
- PTHL $32.00
- MYNZ $10.56
- Technical
- Relative Strength Index (RSI)
- PTHL 44.14
- MYNZ 37.58
- Support Level
- PTHL $0.55
- MYNZ $1.00
- Resistance Level
- PTHL $0.62
- MYNZ $1.13
- Average True Range (ATR)
- PTHL 0.05
- MYNZ 0.21
- MACD
- PTHL 0.02
- MYNZ -0.02
- Stochastic Oscillator
- PTHL 58.80
- MYNZ 14.53
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.